KCNA3 and Parkinson disease: These questions should ideally be addressed both pharmacologically by testing brain penetrant small molecules side by side with peripheral restricted petidic KV1.3 inhibitors or anti-KV1.3 antibodies [58,59] in animal models of Alzheimer’s and Parkinson’s disease.